BMJ Global Health 6: e004812. 2021 ABSTRACT Authorized COVID-19 vaccines must be distributed fairly. Several proposals have emerged offering guidelines for how to do this. However, insofar as the aim is A total of 182 countries have joined the facility so far, which has secured about US$2 billion for its advance market commitment (AMC). The AMC will allow 92 low-income and middle-income countries to obtain vaccine doses as they are approved or authorised. Currently, COVAX is set up so that in a first phase poor countries can vaccinate 3% of their populations, while rich countries can vaccinate up to 50%. Though the facility hopes to allow all members to vaccinate at least 20% of their populations by the end of 2021.Other proposals by theprioritising healthcare workers, the elderly and, those with comorbidities that put them at greater risk of severe illness if infected with COVID-19, people from certain high-risk sociodemographic groups and some teachers.

Human vaccines and immunotherapeutics Abstract Vaccine hesitancy is a threat to global health, but it is not ubiquitous; depending on the country, the proportion that have confidence in vaccines ranges

Reducing populations' vulnerabilities to mis-disinformation related to scientific content

The purpose of this project is to develop evidence-based strategies to address populations’ vulnerabilities to scientific mis-disinformation.

Synthese Abstract The key characteristic of deep disagreements is that any attempt to resolve them just reveals new points of disagreement that stem from underlying commitments. Many moral disagreementsInformal LogicSemantics and Pragmatics

This informal workshop focuses on four papers dealing with a variety of ethical questions associated with the use of age limits, especially in health care. Time: Wednesday, November 23, 14:00 - 18:00Plac The Institute for Futures Studies (IFFS), Holländardgatan 13, Stockholm According to Jeff McMahan, we ought to save an individual, A, from dying as a young adult (e.g., at age 30) rather than save some other individual, B, from dying as a newborn, even if the latter intervention would give B twice as many years of full-quality life as the former intervention would give A.  Call this claim .  I argue that if we accept , then we must reject at least one of three other claims: